Amneal Pharmaceuticals Inc. (AMRX) Revenue-to-Profit Sankey Flow & SEC XBRL Financials
Amneal Pharmaceuticals Inc. (AMRX) receives a Roarable Rating of D+ (Sell) and flashes a Red SELL / AVOID warning (65/100 RQD Confidence). Our SEC filing scanner spotted paper earnings outpacing real operating cash flow (+146.4% (NI vs OCF)) while unpaid customer invoices grew—a classic sign to step aside until cash flow catches up.
How AMRX Turns Every Dollar of Sales Into Real Bottom-Line Profit
Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory
| Fiscal Year | Revenue | Gross Margin | Op Margin | Net Profit | Free Cash Flow | ROIC % |
|---|---|---|---|---|---|---|
| FY 2025 | $3.02B | 36.9% | 13.1% | $72.1M | $269.9M | 14.1% |
| FY 2024 | $2.79B | 36.5% | 8.9% | -$116.9M | $243.2M | 10.1% |
| FY 2023 | $2.39B | 44% | 8.5% | -$84.0M | $237.9M | 6.5% |
Red-Light Warning Desk: How Pros Profit When Overhyped Stocks Crack (Featuring AMRX)
- ✓Live walkthrough of AMRX's RQD Radar, SEC cash-conversion gap & downside levels
- ✓3 asymmetric Bear/Hedge setups institutions use when 10-year yields stay elevated
- ✓Includes instant 24/7 email alert whenever any of your stocks flip to Red
AMRX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +8.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on AMRX today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for AMRX. Explore sector supply chains on /butterfly.
AMRX Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDHow profitable is Amneal Pharmaceuticals Inc. (AMRX)?
In FY 2025 (10-K), AMRX converted $3.0B of revenue into a 36.9% gross margin, 13.1% operating margin, and $269.9M in free cash flow (8.9% FCF margin).